WO1993018174A1 - Composes polymeres de l'acide glucuronique, procede de preparation et utilisation notamment en tant que moyens gelifiants, epaississants, hydratants, stabilisants, chelatants ou floculants - Google Patents
Composes polymeres de l'acide glucuronique, procede de preparation et utilisation notamment en tant que moyens gelifiants, epaississants, hydratants, stabilisants, chelatants ou floculants Download PDFInfo
- Publication number
- WO1993018174A1 WO1993018174A1 PCT/FR1993/000205 FR9300205W WO9318174A1 WO 1993018174 A1 WO1993018174 A1 WO 1993018174A1 FR 9300205 W FR9300205 W FR 9300205W WO 9318174 A1 WO9318174 A1 WO 9318174A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- polyglucuronic
- glucuronic acid
- preparation
- residue
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 68
- 150000001875 compounds Chemical class 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 239000002253 acid Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000000887 hydrating effect Effects 0.000 title claims abstract description 7
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000000855 fermentation Methods 0.000 claims abstract description 34
- 230000004151 fermentation Effects 0.000 claims abstract description 34
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 31
- 241000589196 Sinorhizobium meliloti Species 0.000 claims abstract description 20
- 150000007513 acids Chemical class 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000008719 thickening Effects 0.000 claims abstract description 9
- 238000000746 purification Methods 0.000 claims abstract description 8
- 150000002170 ethers Chemical class 0.000 claims abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 5
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims abstract 9
- 239000002609 medium Substances 0.000 claims description 51
- 241000894006 Bacteria Species 0.000 claims description 24
- 229920001282 polysaccharide Polymers 0.000 claims description 24
- 239000005017 polysaccharide Substances 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 125000003158 alcohol group Chemical group 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 11
- -1 glucuronic acid compound Chemical class 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 241000589180 Rhizobium Species 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000003311 flocculating effect Effects 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 8
- 239000000499 gel Substances 0.000 description 29
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 26
- 150000004804 polysaccharides Chemical class 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
- 229920002674 hyaluronan Polymers 0.000 description 9
- 229960003160 hyaluronic acid Drugs 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000011575 calcium Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000000050 nutritive effect Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229920002201 Oxidized cellulose Polymers 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000011017 operating method Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229940107304 oxidized cellulose Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000219823 Medicago Species 0.000 description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 229920003175 pectinic acid Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
Definitions
- the present invention relates, as new industrial products, to polymeric compounds of glucuronic acid, namely the polyglucuronic linking compounds B (1-4) of formula I below. It also relates to the process for the preparation of these new compounds as well as their use, in particular as gelling, thickening, hydrating, stabilizing, chelating, flocculating, purifying and susceptible to forming fibers, on the one hand, and as starting materials for the preparation of oligosaccharide compounds, on the other hand.
- -It also targets as a new industrial product a particular bacterial strain belonging to all Rhizobium, namely the strain Rhizobium meliloti NCIMB 40472, which is useful in the preparation of said polymeric compounds of glucuronic acid by fermentation.
- the closest prior art known to the owner of the present invention comprises hyaluronic acid described in particular in the work Merck Index, linked edition, (1989), pages 751-752 (product No 4675), of on the one hand, and the polysaccharide described in document FR-A-2 378 092, on the other hand.
- Hyaluronic acid is a natural polysaccharide consisting of a repeating unit with two units: a glucuronic acid unit and a glucosaminidic unit. In this polysaccharide, these two units are alternated; the glucuronic acid unit has a chain p (l-3) and the glucosaminidic unit has a chain B (l-4).
- the structural formula of hyaluronic acid provided in the above-mentioned Merck Index is as follows:
- the polysaccharide of document FR-A-2 378 092 is produced by the exocellular route from a strain of Pseudomo ⁇ as NCIB 11264 (ATCC 31260) and comprises a repeating unit consisting of 7 D-glucose units (a glucose unit substituted in position 6, two units of disubstituted glucose in position 4, two units of glucose substituted in position 3 and two units of disubstituted glucose in positions 4,6) and of 1 unit of substituted D-galactose in position 3, this repeating pattern being esterified with l acetic acid unit and 1 pyruvic acid unit, the side chain of the polymer ending in a 4.6-0- (1-carboxyethylidene) -D-glucose unit.
- Rhizobium meliloti M5N1 (reference given by the holder of the present invention), isolated from the ground, has been described by J. COURTOIS et al., J. Bacteriol. , (1988), 170, pages 5925-5927. Under the fermentation conditions given below, this strain produces polysaccharides having glycosidic bonds p (l-3) and in particular the polymer corresponding to the formula
- said article does not describe or suggest polysaccharides with an average dp greater than 200 ⁇ and in particular with an average dp greater than or equal to 300, according to the invention.
- it neither describes nor suggests the presence or obtaining exclusively D-polyglucuronic polysaccharides with p (l-4) chain and high dp, among the exocellular polysaccharides produced by molds belonging to the order of the mucorals and used as sources of Mw oligosaccharides ranging from 5500 to 10000 daltons.
- the oxidized cellulose obtained according to the process of US-A-2 232 990 is not a polysaccharide of the D-polyglucuronic acid type
- Said oxidized cellulose is different from the polysaccharides of the present invention in particular with regard to the fact (i) that its molecular weight is higher (see US-A-2232 990, page 2 right column, lines 60 64), where it is indicated that the polysaccharide chain of the starting cellulose has not been cleaved), and (ii) that it is insoluble in water (the examples of oxidized cellulose only state its solubility in water containing 2 % NaOH), while the polysaccharides (as well as the oligosaccharides which derive therefrom) according to the present invention are polymers, of the D-polyglucuronic acid type with chain B (1-4) comprising only D-glucuronic acid units, which are all water-soluble.
- the aim of 1 • invention is to provide new polysaccharides that are structurally different from the above-mentioned hyaluronic acid and other polysacchari ⁇ of the prior art, especially polymer products mentioned above and alginates, first , and which are industrially useful in particular as gelling, thickening, hydrating, stabilizing, chelating, flocculating, purifying means capable of forming fibers, intended in particular for the food, dietetic, pharmaceutical fields (in human " or veterinary therapy " ) , cosmetic, agricultural, water purification, paints, on the other hand.
- a new polymer compound of glucuronic acid is recommended, characterized in that it is chosen from the group consisting of
- n is a number having an average value between approximately 300 and 2500
- the aim here is a process for the preparation of a glucuronic acid polymer compound of formula I or one of its esters in which the alcohol OH functions are partially O-acetylated, said process being characterized in that it includes the fermentation, in the presence of a nutritive medium containing a source of nitrogen, a source of carbon and salts, of a bacterial strain belonging to the set of Rhizobium and producing polysaccharides when it is cultivated at pH 7 in an aqueous nutritive medium containing 1 g / 1 of K 2 HP0 4 , 0.2 g of MgS0_ * .7H 2 0, 1 g / 1 of NH4NO3 and 10 g / 1 of glucose.
- the aim is, as a new industrial product, the Rhizobium meliloti NCIMB 40472 strain (reference given by the Holder of the present invention: M5N1 CS) which is obtained by mutation of the above-mentioned wild strain M5N1.
- the use of said polymeric glucuronic acid compounds is pre ⁇ coned, especially in the food, pharmaceutical (in human or veterinary therapy), cosmetic or water purification fields. , in particular as gelling, thickening, hydrating, stabilizing, plasticizing, chelating or flocculating means, or also as film-forming means or forming fibers and fibers.
- the use of said compounds is pre ⁇ coned in the preparation of oligosaccharides which are particularly useful in agriculture. ABBREVIATIONS
- HPLC high performance liquid chromatography
- Ml aqueous identification nutrient medium containing lg / 1 of K 2 HPO ⁇ , 0.2 g of MgS0 4 .7H 2 0, 1 g / 1 of NH.4NO3 and 10 g / 1 of glucose and allowing distinguish by culture at pH 7 the Rhizobium strains which produce PS from those which do not produce
- M2 aqueous nutritive medium of production, preferred according to the invention, containing 1 g / 1 of yeast extract, 1 g / 1 of K 2 HP0 4 , 0.2 g / 1 of MgSO_ a , .7H 2 0 and 10 g / 1 of glucose, fructose or sucrose
- M5N1 wild strain of Rhizobium meliloti described by J. COURTOIS et al., J. Bacteriol. , (1988),
- the polymeric compounds of glucuronic acid according to the invention therefore include the polygluconic acids of formula I, their esters, their ethers and their mixtures. More specifically, such a polymeric compound of glucuronic acid is chosen from one set consisting of
- esters of polyglucuronic acids of formula I in which the OH residue of at least one carboxylic acid group COOH is replaced by a residue, alkoxy in
- esters of polyglucuronic acids of formula I in which the hydrogen atom of at least one alcohol group OH is replaced by an aliphatic acyl residue of C 2 -C *,
- esters of polyglucuronic acids of formula I in which (i) the OH residue of at least one COOH carboxylic acid group is replaced by a C _ -C C * alkoxy residue, and (ii) the hydrogen atom d 'at least one OH alcohol group is replaced by an aliphatic acyl residue in
- ethers of polyglucuronic acids of formula I in which the hydrogen atom of at least one alcohol group OH is replaced by a C ⁇ -C_ * alkyl residue, ether-esters of polyglucuronic acids of formula I wherein (i) the remaining OH of at least one carboxylic acid group COOH is replaced by a radical C -C alkoxy ⁇ , and (ii) the hydrogen atom 'at least one OH alcohol group is replaced by an alkyl residue in
- alkoxy groups in C1-C.4 may be of linear or branched hydrocarbon chain, they include the MeO, EtO, PrO, iPrO, BuO, iBuO, sBuO and tBuO groups.
- C -C4 alkyl groups may have a linear or branched hydrocarbon chain, they include the Me, Et, Pr, iPr, Bu, iBu, sBu and tBu groups.
- Aliphatic acyl groups, C 2 -C ⁇ may be straight or branched hydrocarbon chain, they include groups Ac, COEt, COPc, COiPr.
- the preferred product according to the invention has an Mw of 80,000 to 400,000 daltons and is chosen from the group consisting of
- each glucuronic acid cycle of formula I comprising at most 33% by weight of O-CO-CH3 groups (ie OAc) relative to the weight of said glucuronic acid cycle.
- the acetyloxy function is located either in position 2, or in position 3, or even in positions 2 and 3 of the glucuronic acid cycle.
- the deacetylation is carried out at a pH greater than 8.0 at RT (the pH greater than 8.0 being obtained by means of a strong base, in particular an alkali metal hydroxide such as NaOH or KOH).
- a strong base in particular an alkali metal hydroxide such as NaOH or KOH.
- deacetylated polymer which corresponds to formula I above can be represented by the abbreviated formula: A.gluc B l - [-> 4 A.gluc B l -] perennial-> 4 A.gluc (Io)
- the bacterial strains which are suitable for implementing the preparation process according to the invention, are those which (i) belong to the set of Rhizobium and (ii) produce PS when they are cultivated at pH 7 in an aqueous nutritive medium for identification, namely the medium Ml which contains lg / 1 of K 2 HP0 * , 0.2 g of MgS0 *. 7H 2 0, 1 g / 1 of NH ⁇ N0 3 and 10 g / 1 glucose.
- the process for preparing a polymer compound of glucuronic acid comprises fermentation in the presence of a source of nitrogen, from a carbon and salt source, from a bacterial strain belonging to the set of Rhizobiums which produce PS by culture at pH 7 in the aforementioned aqueous medium Ml.
- the production of said polymer compound can be either intracellular or most often exocellular.
- said fermentation is carried out by means of an aqueous medium containing 0.5 to 2 g / 1 of K 2 HP0 ⁇ , 0.05 to 0.3 g / 1 of MgSO * , 0, 8 to 3 g / 1 of yeast extract and 7 to 20 g / 1 of sugar, at a temperature of 25 to 40 ° C.
- the nutrient medium can contain any sugar, the preferred sugar is chosen in particular from glucose, fructose, sucrose and mixtures thereof.
- the bacteria By incubation in such an aqueous medium, for an appropriate duration (preferably less than or equal to 100 h or, if necessary, more than 100 h), the bacteria produce (both in the growth phase and in the stationary phase of not -proliferation), a polymeric compound of D-glucuronic acid which is the product of formula I or one of its esters in which the alcohol functions OH are partially O-acetylated. From this compound, the other esters and / or ethers are obtained according to a method known per se.
- the aqueous fermentation-incubation medium will contain 1 g / 1 of yeast extract, 1 g / 1 of K ⁇ HPO * ,, 0 , 2 g / 1 of MgS0 ⁇ . 7H 2 0 (source of MgS0 ⁇ ) and 10 g / 1 of sugar (preferably glucose, fructose or sucrose), at a temperature of 30 ° C, at a pH of 7 (obtained by addition of NaOH or KOH), with p0 2 from 30 to 100% (depending on the degree of acetylation desired).
- sugar preferably glucose, fructose or sucrose
- this fermentation is carried out from a bacterial population greater than or equal to 10 2 bacteria / ml and better still greater than or equal to 10 ⁇ bacteria / ml.
- the liquid fermentation medium incubated for a duration of less than or equal to 100 h, which contains the polygluronic polymer compound according to the invention, is collected as soon as the bacterial population is greater than or equal to 10 9 bacteria / ml.
- the bacteria are separated from the fermentation medium, in particular by filtration or dialysis (in particular on a membrane) or else by centrifugation in order to collect said polyglucuronic polymer compound contained in the fermentation juice.
- This polyglucuronic polymer compound is isolated from the resulting filtrate, dialysate or supernatant, either by precipitation using an organic solvent such as EtOH, PrOH, iPrOH, MeCOMe or an analogous solvent, or by precipitation in an acid medium at a lower pH. or equal to 3.
- an organic solvent such as EtOH, PrOH, iPrOH, MeCOMe or an analogous solvent
- the polyglucuronic polymer compound when obtained by precipitation using an organic solvent, it is recommended to operate at low temperature, preferably at a temperature of the order of 4 "C; the precipitate is then collected by centrifugation and then dried (in particular under vacuum at RT).
- the polyglucuronic polymer compound when obtained by precipitation in an acid medium, it is collected by centrifugation, washed with water and dispersed with stirring in an aqueous solution at a pH greater than or equal to 8.0 to be purified; the polyglucuronic polymer compound thus dissolved in an alkaline medium is immediately reprecipitated using an organic solvent as indicated above.
- the esters of the COOH carboxylic acid function can be formed from the deacetylated polymer by alkylation according to a method known per se. It is also possible to obtain the esters of the alcohol OH function by reaction of the deacetylated compound of formula I with an appropriate acid according to a method known per se. The ethers of the OH alcohol function are obtained from said deacetylated compound by application of a reaction mechanism also known per se. The same is true for the esters of the COOH and OH functions and the ether-esters.
- polyglucuronic polymer compounds with chain J3 (l-4) are useful in several fields, namely: the food industry, both human and animal, in particular as thickening or texturing agents; - the paper and board industry, in particular as additives or coating means, or even as fibers;
- polyglucuronic compounds according to the invention have proved to be particularly useful industrially as a replacement for hyaluronic acid in the fields where said hyaluronic acid has hitherto intervened.
- Polyglucuronic compounds, according to the invention are more precisely very effective in human and veterinary therapy, on the one hand, and in surgery, on the other hand, because of their ability to form fibers and threads or yarns.
- the polyglucuronic polymer yarns according to the invention are perfectly suitable for the production of stitches, they have a structure which can be eliminated by biodegradation or treatment with water. Therefore, they have a great analogy with the son made of hyaluronic acid and are very interesting in the field of viscochurgery.
- Polyglucuronic fibers and threads are also very effective in the paper and textile fields.
- the polyglucuronic compounds according to the invention are also useful in the field of the preparation of D-polyglucuronic oligosaccharides with chain B (1-4). More specifically, the OSs are obtained by hydrolysis, in particular acid or enzymatic, of said D-polyglucuronic polymer compounds with chain B (l-4).
- This hydrolysis can be carried out either (i) in the presence of the bacteria Rhizobium meliloti NCIMB 40472, by continuing the fermentation in the medium M2 for more than 100 h, or (ii) by incubation of the polyglucuronic polymer compounds with chain B (l-4 ) or fermentation juice containing them for more than 100 h at a temperature of 20-40 ° C, either (iii) by enzymatic cleavage in particular by means of a cellulase, or (iv) by cleavage in acid medium with a pH less than or equal to 3, for at least 90 hours at 100 ° C.
- the bones thus obtained and then dried have, after isolation, a variable dp from 2 to 10 for short-chain bones, from 10 to 50 for medium-sized bones, and from 50 to 100 approximately for those with a long chain .
- the Preferred OSes according to the invention have a dp of between 5 and 20.
- OS are also useful in the pharmaceutical field, in human and veterinary therapy or in the field of diagnosis, in particular as a means of targeting active ingredients.
- the best mode of carrying out the invention consists in providing a polyglucuronic acid of formula I having an Mw of the order of 80,000 to 400,000 daltons.
- This polyglucuronic acid is obtained from the bacterial strain Rhizobium meliloti NCIMB 40472.
- an aqueous nutrient medium containing 1 g / l of yeast extract, 1 g / l of K 2 HPO_ * , 0.2 g / l of MgS0_ *. 7H 2 0 is sown. and 10 g / 1 of glucose, fructose or sucrose (ie the abovementioned M2 medium), at a temperature of 30 ° C., at a pH of 7, with p0 2 of 30 to 100% by means of said strain Rhizobium meliloti NCIMB 40472 so as to have in the starting fermentation medium for this strain a bacterial population of at least 10 4 bacteria / ml.
- Fermentation is carried out until a bacterial population of at least 10 s bacteria / ml is obtained (it can be continued according to the desired production).
- the bacteria are separated from the fermentation medium by tan filtration. gential on a filter or filter membrane with 200 n porosity.
- the filtrate which contains the optionally acetylated polyglucuronic acid is treated with EtOH, iPrOH or MeCOMe at 4 ° C.
- the precipitate thus obtained is collected by filtration and then dried.
- the polymer thus obtained, redissolved can then be deacetylated at pH 11, for at least 7 h and at most 24 h at RT.
- the total duration of fermentation-incubation of the nutritive medium (M2 medium or analogous medium containing a sugar different from glucose, fructose and sucrose) with the Rhizobium meliloti NCIMB 40472 strain for the production of polysaccharides of formula I and of their corresponding esters (in which the alcohol OH function is partially acetylated) is less than or equal to 100 h, at 30 ° C. and at pH 7.
- This production is carried out (a) during the growth phase of the strain , and / or (b) during the non-proliferation phase thereof after the bacterial population has reached at least the value of 10 9 bacteria / ml.
- the production of the PS of the invention is favored having an Mw located in the upper part of the range 80,000-400,000 daltons; when the duration is greater than 100 h, the production of PS having an Mw located in the lower part of this interval, and of OS is favored.
- the mixture of living bacteria obtained after mutation is seeded on the medium Ml.
- This medium is used to eliminate the bacteria considered here not interesting according to a character of auxotrophy.
- the glucose contained in Ml fulfills two functions: it acts as a carbon source, on the one hand, and it makes it possible to distinguish mutated or non-used bacteria, which do not produce PS, from mutated bacteria producing PS in presence of said glucose.
- the colonies producing PS are cultivated on aniline blue medium.
- the medium with aniline blue makes it possible to distinguish the strains, which respond positively to said medium and have glycosidic bonds B (l-3), from the strains responding negatively which are collected.
- the strains thus collected are analyzed for their content in extrachromosomal DNA (i.e. their plasmid content).
- the direct lysis protocol developed by T.ECKHARDT, Plasmid, (1978), C. pages 584-588, is applied to said strains.
- the plasmid profiles of said strains are compared with that of the wild-type strain M5N1 at the start, in order to identify and retain only the strains having a modified plasmid content.
- This strain thus selected has been (i) checked as regards its infectivity with regard to alfalfa (legume specific for Rhizobium meliloti; the response to infection being positive since only nodules appeared on alfalfa roots), then (ii) deposited with an approved organization.
- This strain is referenced NCIMB 40472. PREPARATION II
- the inoculum of the Rhizobium meliloti NCIMB 40472 strain is introduced [the inoculum consists here of 1 liter of M2 (in Erlenmeyer flask ) containing the strain NCIMB 40472].
- the inoculum is used when the bacterial suspension is of the order of 10 9 bacteria / ml. Fermentation is carried out with the following parameters: temperature 30 ° C pH maintained at 7 (addition of KOH 1M or more) p0 2 30 at 100% (depending on the degree of acetylation desired) stirring 100 rpm
- the medium can contain 1 to 5 gl _i.
- the yield relative to the sugar in the M2 medium thus varies between 20 and 85% (the measurements are carried out by HPLC chromatography with a Beckman TSK 2000 SW column and detection by refractometry).
- the cells are cultured under the conditions (inoculum / medium) described in preparation II above.
- the suspension in the fermenter reaches 10 9 bacteria / ml of Rhizobium meliloti NCIMB 40472, the fermentation medium is passed through microfiltration membranes (200 n of porosity), the cells are washed and recovered (they can be recovered directly by continuous centrifugation under sterile conditions).
- These cells are washed using a nitrogen-free medium comprising: and then introduced into a fermenter containing 15 liters of medium devoid of nitrogen but supplemented with 10 g / 1 of glucose, fructose or sucrose.
- the fermenter thus inoculated at a bacterial concentration of approximately 10 9 bacteria / ml is subjected to the same parameters as in the case of a growing production.
- the medium contains the same polymer as that of preparation II at a concentration similar to that of the growing fermentation.
- the bacteria are eliminated from the fermen ⁇ tation medium by filtration (in particular tangential filtration on a 200 nm porosity filter, in particular the MICROSART MINI filter sold by the company SARTORIUS) or by centrifugation of the fermentation medium of the preparation II, III or IV.
- the polyglucuronic compound with chain p (l-4) is recovered from the filtrate or from the supernatant by precipitation with an organic solvent such as EtOH, iPrOH or MeCOMe.
- an organic solvent such as EtOH, iPrOH or MeCOMe.
- iPrOH this solvent is added to the filtrate in a proportion of 70% v / v, if necessary in the presence of 1M NaCl.
- the resulting assembly is homogenized and a precipitate of poly ⁇ glucuronic compound is formed (precipitation is favored at low temperature, in particular at + 4 ° C.).
- the precipitate is collected by centrifugation and dried under vacuum at RT.
- the filtrate or supernatant obtained according to step (a) of preparation V is purified by tangential ultrafiltration with a membrane whose porosity is between 60,000 and 80,000 daltons. To purify the concen ⁇ trate, the filtrate is removed and replaced with distilled water. This operation is repeated until the desired purification is reached.
- the polygluonic curonic polymer B (l-4) is isolated by evaporation under vacuum at RT.
- PREPARATION VIII Deacetylation The isolated polymer obtained according to preparation VII which contains at most 33% by weight of group OAc relative to the weight of the glucuronic acid repeating unit is treated at a pH greater than 8 by means of NaOH. Overnight at RT and at pH 11 allows the molecule to be deacetylated. ANALYZES
- the products of preparations V-VIII are D-polyglucuronic polymer compounds exclusively constituted by D-glucuronic acid units, and having a p (l-4) sequence; 2 e ) the products of preparations V-VII are partially acetylated D-glucuronic acid polymer compounds (at most 33% by weight as indicated above) in position 2, in position 3 or in positions 2 and 3; 3) the product of preparation VIII is deacetylated.
- the solutions of the polyglucuronic compound according to preparations V-VIII are stable when cold in an alkaline medium, in particular at pH 11; if the temperature rises, the OAc substituents are cleaved. This polyglucuronic compound is also stable in an acid medium but precipitates at a pH of around 3.
- the intrinsic viscosity (Vi) in 0.1 M NaCl is 650 ml / g for an Mw of 150,000 (the Mw can vary depending on the duration of fermentation between 80,000 and 400,000 dal ⁇ tons and better between 100,000 and 350,000 daltons).
- This intrinsic viscosity is low compared to that of the succinoglycan produced by the wild strain Rhizobium meliloti M5N1 which has a Vi of 5,480 ml / g for a Hw of 4,000,000 daltons.
- the results obtained with regard to this intrinsic viscosity are comparable to those of an alginate having an Mw of 270,000 daltons.
- solutions of polyglucuro ⁇ nic polymer compounds according to the invention having an Mw greater than 300,000 daltons at concentrations of 20 to 30 g / 1 form a few minutes after their homogenization of thermoreversible firm gels.
- the polymer according to the invention having an Mw of the order of 80,000 dal ⁇ tons gives a few minutes after its homogenization a flexible gel.
- the solutions of the polymers according to the invention behave like thickeners.
- the monovalent ions form gels with the solutions of the polyglucuronic polymers according to the invention. These gels are thermoreversible. The formation of the gel depends on the nature of the cation, on the ionic strength and on the concentration, the ion selectivity being the following: Na- ⁇ Li- ⁇ K * ⁇ MU-.
- the transition temperature depends on the concentration of NH 4 - * - (NH_ * C1 from 0.5 M to 1.5 M or more) and the rate of acetate in the molecule.
- the gel formed with 0.5 M NH 4 Cl and the polyglucuronic compound according to the invention at a concentration of 10 to 15 g / l, brought to 100 ° C. for 24 h is practically not degraded.
- the polysaccharide forms a gel which is comparable to those of pectinic acids (substances of the polygalacturonic acid type) and of alginates (substances of the copoly type of mannuronic acid / guluronic acid era).
- pectinic acids substances of the polygalacturonic acid type
- alginates substances of the copoly type of mannuronic acid / guluronic acid era
- the polyglucuronic polymer compound according to the invention in solution in water and placed in the presence of MgCl 2 is capable of forming a thermoreversible gel.
- the gels can be formed directly in contact with Ca 2- * - and polyglucuronic polymer compounds with p (l-4) sequence by dialysis or any other method allowing progressive contact between the ion and said polymer compounds.
- these gels can be formed using reagents allowing progressive gelling: it is thus possible to form a gel from a polymer compound at 10 g / 1 in water and CaHPO4.2H 2 0 (at the concentration of 1.2 to 1.5 g / 1) and gluconolactone (at the concentration of 4.5 g / 1), after homogenization, the gel forms in the preparation kept immobile.
- Firm gels can be obtained from concentrations of polyglucuronic polymer compound according to the invention of the order of 3 g / 1.
- the gel brought to a temperature of 100 "C for 1.5 h does not undergo any modification, the strength of the gel (module) is unchanged after 24 h (compression measurement carried out on an INSTR ⁇ N device) ,
- the gel placed at 100 ° C at pH below 2 is stable for at least 1 h
- the gel placed at 100 ° C at pH 8-13 is stable for at least 1 h, - in CaCl 2 , 0.34 M, the gel is stable for at least 24 h; at RT
- the gel is stable (in one week, the module goes from 1.8 to 1.3 N / cm 2 ),
- the gel is maintained for at least a week
- the water of said polyglucuronic polymers from the concentration of 3 g / 1, brought into contact with an alcohol, in particular EtOH, form gels.
- fibers can be obtained from polymer / CaCl 2 gels.
- X-ray shots on polymer fibers / CaCl 2 show a periodicity along the axis of each fiber of the order of 103 nm. Such a periodicity is analogous to that found for cellulose.
- the present preparation illustrates the obtaining of OS in the growth medium and in the presence of Rhizobium meliloti bacteria NCIMB 40472.
- a fermentation is carried out in a growth medium according to the operating methods described. in preparation II above, with the difference that the duration of said fermentation is greater (preferably) or equal to 100 h at RT to obtain a relatively large amount of OS. This prolonged hydrolysis leads to the formation of bone in the medium.
- the bacteria are separated from the fermentation medium by centrifugation or tangential microfiltration using filters with a porosity of 200 nm.
- the OS compound is recovered by ultrafiltration, purified by chromatography and dried. It has a dp of 5-60 and can be separated into three fractions of (a) dp 5-10, (b) dp 10-50 and (c) dp 50-60, in particular by chromatography.
- PREPARATION X Obtaining an oligosaccharide compound
- the present preparation illustrates the obtaining of OS in the absence of bacteria.
- step (b) The isolation of the OS compound formed in said liquid medium is carried out as indicated in step (b) of preparation IX. After ultrafiltration, purification and drying, an OS having a dp of 5-60 is obtained and separated ble in three fractions of dp 5-10, 10-50 and 50-60. PREPARATION XI
- the present preparation illustrates the obtaining of OS by enzymatic hydrolysis.
- the present preparation illustrates the obtaining of OS by acid hydrolysis.
- step (b) The isolation of the OS compound thus obtained is carried out as indicated in step (b) of preparation IX. After ultrafiltration, purification and drying, an OS is obtained having a dp of 5-60 separable into three fractions of dp 5-10, 10-50 and 50-60.
- glucuronic acid obtained by deacetylation according to the operating methods described in preparation VIII was subjected to extensive enzymatic hydrolysis so as to provide the glucuronic acid.
- the glucuronic acid thus formed can be isolated by ultrafiltration and purified by ion exchange chromatography, by electrodialysis or any other suitable method making it possible to separate said acid from the larger molecules and from the salts present in the hydrolysis medium. enzymatic.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93905441A EP0629245A1 (fr) | 1992-03-03 | 1993-03-01 | Composes polymeres de l'acide glucuronique, procede de preparation et utilisation notamment en tant que moyens gelifiants, epaississants, hydratants, stabilisants, chelatants ou floculants |
JP5515378A JPH07504928A (ja) | 1992-03-03 | 1993-03-01 | 高分子グルクロン酸化合物,その製造方法及び用途,特にゲル化剤,粘度付与剤,湿気付与剤,安定剤,キレート化剤又は凝集剤としての用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR92/02510 | 1992-03-03 | ||
FR9202510A FR2688222B1 (fr) | 1992-03-03 | 1992-03-03 | Composes polymeres de l'acide glucuronique, procede de preparation et utilisation notamment en tant que moyens gelifiants, epaississants, hydratants, stabilisants, chelatants ou floculants. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993018174A1 true WO1993018174A1 (fr) | 1993-09-16 |
Family
ID=9427280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1993/000205 WO1993018174A1 (fr) | 1992-03-03 | 1993-03-01 | Composes polymeres de l'acide glucuronique, procede de preparation et utilisation notamment en tant que moyens gelifiants, epaississants, hydratants, stabilisants, chelatants ou floculants |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0629245A1 (fr) |
JP (1) | JPH07504928A (fr) |
CA (1) | CA2131384A1 (fr) |
FR (1) | FR2688222B1 (fr) |
WO (1) | WO1993018174A1 (fr) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2781673A1 (fr) * | 1998-07-28 | 2000-02-04 | Univ Picardie | Utilisation d'un glucuronane en tant qu'agent immunostimulant, procede de preparation |
WO2010067327A1 (fr) | 2008-12-11 | 2010-06-17 | Sederma | Composition cosmétique contenant des oligoglucuronanes acétylés |
US20110150795A1 (en) * | 2008-04-15 | 2011-06-23 | Innovactiv Inc. | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof |
WO2014049055A2 (fr) | 2012-09-27 | 2014-04-03 | Sofradim Production | Procédé de préparation d'une couche poreuse |
US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
US9445883B2 (en) | 2011-12-29 | 2016-09-20 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US9499927B2 (en) | 2012-09-25 | 2016-11-22 | Sofradim Production | Method for producing a prosthesis for reinforcing the abdominal wall |
US9526603B2 (en) | 2011-09-30 | 2016-12-27 | Covidien Lp | Reversible stiffening of light weight mesh |
US9554887B2 (en) | 2011-03-16 | 2017-01-31 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US9622843B2 (en) | 2011-07-13 | 2017-04-18 | Sofradim Production | Umbilical hernia prosthesis |
US9750837B2 (en) | 2012-09-25 | 2017-09-05 | Sofradim Production | Haemostatic patch and method of preparation |
US9839505B2 (en) | 2012-09-25 | 2017-12-12 | Sofradim Production | Prosthesis comprising a mesh and a strengthening means |
US9877820B2 (en) | 2014-09-29 | 2018-01-30 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US9932695B2 (en) | 2014-12-05 | 2018-04-03 | Sofradim Production | Prosthetic porous knit |
US9931198B2 (en) | 2015-04-24 | 2018-04-03 | Sofradim Production | Prosthesis for supporting a breast structure |
US9980802B2 (en) | 2011-07-13 | 2018-05-29 | Sofradim Production | Umbilical hernia prosthesis |
US10080639B2 (en) | 2011-12-29 | 2018-09-25 | Sofradim Production | Prosthesis for inguinal hernia |
US10159555B2 (en) | 2012-09-28 | 2018-12-25 | Sofradim Production | Packaging for a hernia repair device |
US10184032B2 (en) | 2015-02-17 | 2019-01-22 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
US10213283B2 (en) | 2013-06-07 | 2019-02-26 | Sofradim Production | Textile-based prosthesis for laparoscopic surgery |
US10327882B2 (en) | 2014-09-29 | 2019-06-25 | Sofradim Production | Whale concept—folding mesh for TIPP procedure for inguinal hernia |
US10363690B2 (en) | 2012-08-02 | 2019-07-30 | Sofradim Production | Method for preparing a chitosan-based porous layer |
US10405960B2 (en) | 2013-06-07 | 2019-09-10 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US10549015B2 (en) | 2014-09-24 | 2020-02-04 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
US10646321B2 (en) | 2016-01-25 | 2020-05-12 | Sofradim Production | Prosthesis for hernia repair |
US10675137B2 (en) | 2017-05-02 | 2020-06-09 | Sofradim Production | Prosthesis for inguinal hernia repair |
US10682215B2 (en) | 2016-10-21 | 2020-06-16 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US10743976B2 (en) | 2015-06-19 | 2020-08-18 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US10865505B2 (en) | 2009-09-04 | 2020-12-15 | Sofradim Production | Gripping fabric coated with a bioresorbable impenetrable layer |
US11471257B2 (en) | 2018-11-16 | 2022-10-18 | Sofradim Production | Implants suitable for soft tissue repair |
EP4089163A1 (fr) | 2021-05-11 | 2022-11-16 | Université Clermont Auvergne | Composé polymère d'acide glucuronique avec des groupes phénoliques, composition formant un gel comprenant un tel composé et son procédé de production |
US20230220117A1 (en) * | 2021-03-08 | 2023-07-13 | Exopolymer, Inc. | Biopolymers for Topical Use |
US12064330B2 (en) | 2020-04-28 | 2024-08-20 | Covidien Lp | Implantable prothesis for minimally invasive hernia repair |
US12258689B2 (en) | 2011-03-16 | 2025-03-25 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2768335B1 (fr) * | 1997-09-12 | 2000-03-03 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant une association d'extrait d'algue et d'exopolysaccharide |
FR2795289B1 (fr) | 1999-06-25 | 2005-09-30 | Centre Nat Rech Scient | Utilisation de polymeres 1,4 beta-d-glycuronanes et d'oligosaccharides glycuroniques derives en tant que phytosanitaires et/ou fertilisants |
JP2005015680A (ja) * | 2003-06-27 | 2005-01-20 | Toppan Printing Co Ltd | ポリグルクロン酸 |
JP5331994B2 (ja) * | 2005-09-02 | 2013-10-30 | オールトレイセル・ディベロップメント・サービシズ・リミテッド | ポリアンヒドログルクロン酸塩を調製する方法 |
US8455460B2 (en) * | 2007-08-31 | 2013-06-04 | Greentech | Cosmetic composition containing one or more compounds of the β-(1,3)-glucuronan or β-(1,3)-glucoglucuronan type |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2232990A (en) * | 1938-07-15 | 1941-02-25 | Eastman Kodak Co | Preparation of oxycellulose |
-
1992
- 1992-03-03 FR FR9202510A patent/FR2688222B1/fr not_active Expired - Fee Related
-
1993
- 1993-03-01 WO PCT/FR1993/000205 patent/WO1993018174A1/fr not_active Application Discontinuation
- 1993-03-01 CA CA002131384A patent/CA2131384A1/fr not_active Abandoned
- 1993-03-01 JP JP5515378A patent/JPH07504928A/ja active Pending
- 1993-03-01 EP EP93905441A patent/EP0629245A1/fr not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 14, no. 294 (C-732)26 Juin 1990 * |
PATENT ABSTRACTS OF JAPAN vol. 7, no. 235 (C-191)19 Octobre 1983 * |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2781673A1 (fr) * | 1998-07-28 | 2000-02-04 | Univ Picardie | Utilisation d'un glucuronane en tant qu'agent immunostimulant, procede de preparation |
US10368971B2 (en) | 2007-12-03 | 2019-08-06 | Sofradim Production | Implant for parastomal hernia |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
US11040058B2 (en) | 2008-04-15 | 2021-06-22 | Lucas Meyer Cosmetics Canada Inc. | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and methods of use thereof |
US20110150795A1 (en) * | 2008-04-15 | 2011-06-23 | Innovactiv Inc. | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof |
US11752168B2 (en) | 2008-04-15 | 2023-09-12 | Lucas Meyer Cosmetics Canada Inc. | Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats |
US10070948B2 (en) | 2008-06-27 | 2018-09-11 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US20150196475A1 (en) * | 2008-12-11 | 2015-07-16 | Sederma, S.A.S. | Cosmetic Composition Containing Acetylated Oligoglucuronans |
FR2939799A1 (fr) * | 2008-12-11 | 2010-06-18 | Sederma Sa | Composition cosmetique comprenant des oligoglucuronanes acetyles. |
US10159636B2 (en) | 2008-12-11 | 2018-12-25 | Sederma, S.A.S. | Cosmetic composition containing acetylated oligoglucuronans |
WO2010067327A1 (fr) | 2008-12-11 | 2010-06-17 | Sederma | Composition cosmétique contenant des oligoglucuronanes acétylés |
US10865505B2 (en) | 2009-09-04 | 2020-12-15 | Sofradim Production | Gripping fabric coated with a bioresorbable impenetrable layer |
US11970798B2 (en) | 2009-09-04 | 2024-04-30 | Sofradim Production | Gripping fabric coated with a bioresorbable impenetrable layer |
US9554887B2 (en) | 2011-03-16 | 2017-01-31 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US11612472B2 (en) | 2011-03-16 | 2023-03-28 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US12258689B2 (en) | 2011-03-16 | 2025-03-25 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US10472750B2 (en) | 2011-03-16 | 2019-11-12 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US9622843B2 (en) | 2011-07-13 | 2017-04-18 | Sofradim Production | Umbilical hernia prosthesis |
US9980802B2 (en) | 2011-07-13 | 2018-05-29 | Sofradim Production | Umbilical hernia prosthesis |
US11903807B2 (en) | 2011-07-13 | 2024-02-20 | Sofradim Production | Umbilical hernia prosthesis |
US11039912B2 (en) | 2011-07-13 | 2021-06-22 | Sofradim Production | Umbilical hernia prosthesis |
US10709538B2 (en) | 2011-07-13 | 2020-07-14 | Sofradim Production | Umbilical hernia prosthesis |
US9526603B2 (en) | 2011-09-30 | 2016-12-27 | Covidien Lp | Reversible stiffening of light weight mesh |
US11925543B2 (en) | 2011-12-29 | 2024-03-12 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US10342652B2 (en) | 2011-12-29 | 2019-07-09 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US9445883B2 (en) | 2011-12-29 | 2016-09-20 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US10080639B2 (en) | 2011-12-29 | 2018-09-25 | Sofradim Production | Prosthesis for inguinal hernia |
US11266489B2 (en) | 2011-12-29 | 2022-03-08 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US11471256B2 (en) | 2011-12-29 | 2022-10-18 | Sofradim Production | Prosthesis for inguinal hernia |
US10363690B2 (en) | 2012-08-02 | 2019-07-30 | Sofradim Production | Method for preparing a chitosan-based porous layer |
US9839505B2 (en) | 2012-09-25 | 2017-12-12 | Sofradim Production | Prosthesis comprising a mesh and a strengthening means |
US9499927B2 (en) | 2012-09-25 | 2016-11-22 | Sofradim Production | Method for producing a prosthesis for reinforcing the abdominal wall |
US9750837B2 (en) | 2012-09-25 | 2017-09-05 | Sofradim Production | Haemostatic patch and method of preparation |
WO2014049055A2 (fr) | 2012-09-27 | 2014-04-03 | Sofradim Production | Procédé de préparation d'une couche poreuse |
US10159555B2 (en) | 2012-09-28 | 2018-12-25 | Sofradim Production | Packaging for a hernia repair device |
US11622845B2 (en) | 2013-06-07 | 2023-04-11 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US12059338B2 (en) | 2013-06-07 | 2024-08-13 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US11304790B2 (en) | 2013-06-07 | 2022-04-19 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US10405960B2 (en) | 2013-06-07 | 2019-09-10 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US10213283B2 (en) | 2013-06-07 | 2019-02-26 | Sofradim Production | Textile-based prosthesis for laparoscopic surgery |
US12070534B2 (en) | 2014-09-24 | 2024-08-27 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
US10549015B2 (en) | 2014-09-24 | 2020-02-04 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
US11589974B2 (en) | 2014-09-29 | 2023-02-28 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US11291536B2 (en) | 2014-09-29 | 2022-04-05 | Sofradim Production | Whale concept-folding mesh for TIPP procedure for inguinal hernia |
US9877820B2 (en) | 2014-09-29 | 2018-01-30 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US10327882B2 (en) | 2014-09-29 | 2019-06-25 | Sofradim Production | Whale concept—folding mesh for TIPP procedure for inguinal hernia |
US10653508B2 (en) | 2014-09-29 | 2020-05-19 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US11713526B2 (en) | 2014-12-05 | 2023-08-01 | Sofradim Production | Prosthetic porous knit |
US11359313B2 (en) | 2014-12-05 | 2022-06-14 | Sofradim Production | Prosthetic porous knit |
US12091788B2 (en) | 2014-12-05 | 2024-09-17 | Sofradim Production | Prosthetic porous knit |
US9932695B2 (en) | 2014-12-05 | 2018-04-03 | Sofradim Production | Prosthetic porous knit |
US10745835B2 (en) | 2014-12-05 | 2020-08-18 | Sofradim Production | Prosthetic porous knit |
US10184032B2 (en) | 2015-02-17 | 2019-01-22 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
US10815345B2 (en) | 2015-02-17 | 2020-10-27 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
US9931198B2 (en) | 2015-04-24 | 2018-04-03 | Sofradim Production | Prosthesis for supporting a breast structure |
US10660741B2 (en) | 2015-04-24 | 2020-05-26 | Sofradim Production | Prosthesis for supporting a breast structure |
US11439498B2 (en) | 2015-04-24 | 2022-09-13 | Sofradim Production | Prosthesis for supporting a breast structure |
US12161547B2 (en) | 2015-04-24 | 2024-12-10 | Sofradim Production | Prosthesis for supporting a breast structure |
US11826242B2 (en) | 2015-06-19 | 2023-11-28 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US12257137B2 (en) | 2015-06-19 | 2025-03-25 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US10743976B2 (en) | 2015-06-19 | 2020-08-18 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US10646321B2 (en) | 2016-01-25 | 2020-05-12 | Sofradim Production | Prosthesis for hernia repair |
US11389282B2 (en) | 2016-01-25 | 2022-07-19 | Sofradim Production | Prosthesis for hernia repair |
US11696819B2 (en) | 2016-10-21 | 2023-07-11 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US10682215B2 (en) | 2016-10-21 | 2020-06-16 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US11672636B2 (en) | 2017-05-02 | 2023-06-13 | Sofradim Production | Prosthesis for inguinal hernia repair |
US10675137B2 (en) | 2017-05-02 | 2020-06-09 | Sofradim Production | Prosthesis for inguinal hernia repair |
US11471257B2 (en) | 2018-11-16 | 2022-10-18 | Sofradim Production | Implants suitable for soft tissue repair |
US12064330B2 (en) | 2020-04-28 | 2024-08-20 | Covidien Lp | Implantable prothesis for minimally invasive hernia repair |
US12202912B2 (en) * | 2021-03-08 | 2025-01-21 | Exopolymer, Inc. | Biopolymers for topical use |
US20230220117A1 (en) * | 2021-03-08 | 2023-07-13 | Exopolymer, Inc. | Biopolymers for Topical Use |
EP4089163A1 (fr) | 2021-05-11 | 2022-11-16 | Université Clermont Auvergne | Composé polymère d'acide glucuronique avec des groupes phénoliques, composition formant un gel comprenant un tel composé et son procédé de production |
WO2022238441A1 (fr) | 2021-05-11 | 2022-11-17 | Universite Clermont Auvergne | Composé polymère d'acide glucuronique à groupes phénoliques, composition de formation de gel comprenant un tel composé et son procédé de production |
Also Published As
Publication number | Publication date |
---|---|
JPH07504928A (ja) | 1995-06-01 |
EP0629245A1 (fr) | 1994-12-21 |
CA2131384A1 (fr) | 1993-09-16 |
FR2688222A1 (fr) | 1993-09-10 |
FR2688222B1 (fr) | 1995-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993018174A1 (fr) | Composes polymeres de l'acide glucuronique, procede de preparation et utilisation notamment en tant que moyens gelifiants, epaississants, hydratants, stabilisants, chelatants ou floculants | |
CN101512006B (zh) | 用于纯化高分子量透明质酸的有效方法 | |
JPH06505146A (ja) | ヒアルロン酸の製造 | |
WO2012168618A1 (fr) | Extraction de chitines en une seule étape par hydrolyse enzymatique en milieu acide | |
EP2321419B1 (fr) | Procédé de co-production de chitine, de ses dérivés et de polymères contenant du glucose, du mannose et/ou du galactose, par la fermentation de levure pichia pastoris dsmz 70877 | |
CH634855A5 (fr) | Procede de production de nouveaux derives de beta-1,3-glucanes. | |
CH692919A5 (fr) | Procédé de purification de l'acide hyaluronique à poids moléculaire élevé. | |
JP5969390B2 (ja) | フコース含有細菌バイオポリマー | |
JP3181337B2 (ja) | キトサンオリゴ糖混合物の製造方法、及びキチンオリゴ糖混合物の製造方法 | |
JPH07119243B2 (ja) | β−グルカン及びその製造方法 | |
EP1121453B1 (fr) | Heteropolysacchardie produit par un agrobacterium radiobacter | |
FR2781673A1 (fr) | Utilisation d'un glucuronane en tant qu'agent immunostimulant, procede de preparation | |
FR2990696A1 (fr) | Souche productrice de turanose et utilisations | |
EP1603394A1 (fr) | Procede pour la potentialisation et la stimulation des defenses naturelles des plantes | |
FR2906819A1 (fr) | Nouveau polysaccharide,son procede de preparation et ses utilisations notamment dans le domaine cosmetique | |
EP0979301B1 (fr) | Souche de pseudomonas alginovora productrice d'alginate-lyase et son utilisation pour la depolymerisation d'alginate | |
KR101858733B1 (ko) | 초저분자량 히알루론산의 제조방법 | |
JP3064052B2 (ja) | 微細藻類から多糖類を生産する方法 | |
FI105346B (fi) | Fermentointiprosessi ksantaanikumin valmistamiseksi | |
EP0296965B1 (fr) | Procédé de fermentation pour l'obtention d'un polysaccharide de type xanthane | |
FR2792337A1 (fr) | Heteropolysaccharide produit par un pseudomonas sp | |
JP3826168B2 (ja) | 微生物由来の多糖類 | |
FR2687686A1 (fr) | Enzyme destinee a la fragmentation du n-acetylheparosane, obtention des preparations contenant cette enzyme et procedes de fragmentation utilisant cette enzyme. | |
JPH04268301A (ja) | 新規なセルロースおよびその製造法 | |
JPS62257901A (ja) | ヒアルロン酸の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA HU JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993905441 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 290997 Country of ref document: US Date of ref document: 19940829 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2131384 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1993905441 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993905441 Country of ref document: EP |